NCT01772836View on ClinicalTrials.gov

Safety Study of Intravenous Biapenem (RPX2003) and RPX7009 Given Alone and in Combination

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions
Healthy VolunteersBacterial Infections
Interventions
DRUG

RPX7009

Up to three (3) cohorts of 10 healthy adult subjects (8 active, 2 placebo)

DRUG

Biapenem

Up to three (3) cohorts of 10 healthy adult subjects (8 active, 2 placebo)

DRUG

Normal saline

Up to three (3) cohorts of 10 healthy adult subjects (8 active, 2 placebo)

Trial Locations (1)

5000

CMAX, Adelaide

All Listed Sponsors
lead

Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)

INDUSTRY

NCT01772836 - Safety Study of Intravenous Biapenem (RPX2003) and RPX7009 Given Alone and in Combination | Biotech Hunter | Biotech Hunter